All I'm saying is Novartis looked under the hood and walked away.
..... yes on the FDA Supports Accelerated Approval for CHF thread and 'inferring' that Novartis walked away from everything when their partnership agreement was only for Remestemcel-L and COVID-19 ARDS, which most docs would know has nothing to do with the Rexlemestrocel-L CHF indication .... as you were - I can't be bothered
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-432
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |